Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens-Reference-Cited by-同舟云学术

Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens

Published:2015-01 Issue:1 Volume:31 Page:71-77
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Baroncelli Silvia¹,Pirillo Maria Franca¹,Galluzzo Clementina Maria¹,Antoni Anna Degli²,Ladisa Nicoletta³,Francisci Daniela⁴,d'Ettorre Gabriella⁵,Segala Daniela⁶,Vivarelli Angela⁷,Sozio Federica⁸,Cirioni Oscar⁹,Weimer Liliana Elena¹,Fragola Vincenzo¹,Parruti Giustino⁸,Floridia Marco¹

Affiliation:

1. Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy.

2. Department of Infectious Diseases and Hepatology, Azienda Ospedaliera di Parma, Parma, Italy.

3. Division of Infectious Disease University of Bari, Bari, Italy.

4. Division of Infectious Diseases, Department of Experimental Medicine, University of Perugia, Perugia, Italy.

5. Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.

6. Infectious Diseases Unit, Arcispedale S. Anna, Ferrara, Italy.

7. Infectious Diseases Unit, Ospedale Civile, Pistoia, Italy.

8. Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy.

9. Clinic of Infectious Diseases, Ospedali Riuniti, Marche Polytechnic University, Ancona, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2014.0060

Reference47 articles.

1. Predictors of Residual Viremia in HIV‐Infected Patients Successfully Treated with Efavirenz and Lamivudine plus either Tenofovir or Stavudine

2. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

3. Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral Therapy

4. HIV RNA Suppression and Immune Restoration: Can We Do Better?

5. Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study;Viruses;2023-08-12

2. Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV;PLOS ONE;2022-02-03

3. Prevalence and risk of residual viremia after ART in low- and middle-income countries;Medicine;2021-09-03

4. Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART.;EBioMedicine;2021-04

5. Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy;Open Forum Infectious Diseases;2020-04-02